2018 Prior Authorization (PA) Criteria

Transcription

1 2018 Prior Authorization (PA) Certain drugs require prior authorization from GuildNet Gold Plus FIDA Plan Medicare Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered. This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and to provide information describing the use and administration of the drug so we can advise on whether the drug will be covered. To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for.

2 ACTHAR Acthar H.P. PA All FDA-approved indications not otherwise excluded from Part D. Other Use in patients with multiple sclerosis (MS) as pulse therapy on a monthly basis. Use as maintenance therapy in patients with psoriatic arthritis, rheumatoid arthritis, or ankylosing spondylitis. Treatment of proteinuria in diabetic nephropathy. MS exacerbation, rheumatic disorder exacerbation, history of corticosteroid use, concomitant use of disease-modifying antirheumatic drugs (DMARDs). Infantile spasms, prescribed by or in consultation with a neurologist or an epileptologist. MS exacerbation, prescribed by or in consultation with a neurologist or physician that specializes in the treatment of MS. Rheumatic disorder exacerbation, prescribed by or in consultation with a rheumatologist. One month For MS exacerbation and rheumatic disorder exacerbation, approve if the patient cannot use high-dose IV corticosteroids because IV access is not possible or if the patient has tried high-dose corticosteroids administered IV for an acute exacerbation and has experienced a severe or limiting adverse effect. 1

3 ACTIMMUNE Actimmune PA Other All FDA approved indications not otherwise excluded from Part D 2

4 ADCIRCA Adcirca PA Other All FDA approved indications not otherwise excluded from Part D Nitrate therapy PAH been confirmed by right heart catheterization. 3

5 ADEMPAS Adempas PA All FDA-approved indications not otherwise excluded from Part D. Other PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist. For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is not required in pts who are currently receiving Adempas or another agent indicated for WHO group 1. 4

6 AFINITOR Afinitor Afinitor Disperz PA Other All FDA approved indications not otherwise excluded from Part D Oncologist 5

7 ALECENSA Alecensa PA All FDA-approved indications not otherwise excluded from Part D. Patients already started on Alecensa for a covered use Other Xalkori (Crizotinib) treatment naive patients Confirmed ALK-positive NSCLC as detected by an FDA-approved test and prior therapies tried 18 years and older Prescribed by, or in consultation with, an Oncologist Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC): The patient has metastatic ALK-positive NSCLC as detected by an FDA-approved test AND The patient has progressed on or are intolerant to Xalkori (crizotinib) 6

8 ALIQOPA Aliqopa PA Other All FDA-approved indications not otherwise excluded from Part D Treatment naive patients Diagnosis, previous therapies tried 18 years of age or older Prescribed by, or in consultation with, an oncologist For follicular lymphoma, patients must have received at least 2 prior systemic therapies 7

9 ALOSETRON alosetron PA Other All FDA-approved indications not otherwise excluded from Part D coverage Patient has a history of any of the following conditions: Chronic or severe constipation or sequelae from constipation. Intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions. Ischemic colitis. Impaired intestinal circulation, thrombophlebitis or hypercoagulable state. Crohn's disease or ulcerative colitis. Diverticulitis. Severe hepatic impairment. For diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) alosetron is being prescribed for a woman AND chronic IBS symptoms have lasted at least 6 months AND gastrointestinal tract abnormalities have been ruled out AND the patient has had inadequate response to conventional therapy. 8

10 ALUNBRIG Alunbrig oral tablet 180 mg, 30 mg, 90 mg Alunbrig oral tablets,dose pack PA Other All FDA-approved indications not otherwise excluded from Part D Concurrent use with other chemotherapy, patients with ALK-negative NSCLC, pediatric patients less than 18 years of age Diagnosis, prior therapies, ALK-positive NSCLC confirmed by an FDAapproved test 18 years or older Prescribed by or in consultation with an oncologist For NSCLC, patient has metastatic or recurrent disease that is ALKpositive as detected by an FDA-approved test AND Alunbrig is being used as a single agent AND patient has progressed on Xalkori (crizotinib) 9

11 AMPYRA Ampyra PA Other All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on dalfampridine extended-release for Multiple Sclerosis (MS). MS. If prescribed by, or in consultation with, a neurologist or MS specialist. 10

12 ANADROL Anadrol-50 PA Other All FDA-approved indications not otherwise excluded from Part D 11

13 ANTICONVULSANTS topiramate oral capsule, sprinkle topiramate oral capsule,sprinkle,er 24hr topiramate oral tablet zonisamide PA Other All FDA approved indications not otherwise excluded from Part D 12

14 APOKYN APOKYN PA Other All FDA-approved indications not otherwise excluded from Part D 13

15 APTIOM Aptiom PA Other All FDA-approved indications not otherwise excluded from Part D 14

16 ARCALYST Arcalyst PA Other All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on rilonacept for Muckle Wells Syndrome (MWS) or Familial Cold Autoinflammatory Syndrome (FCAS). Rilonacept should not be given in combination with biologic therapy (e.g. tumor necrosis factor (TNF) blocking agents (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), anakinra, or canakinumab). Initial tx CAPS-Greater than or equal to 12 years of age. Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, dermatologist or immunologist. CAPS renewal - approve if they have had a response and are continuing therapy to maintain response/remission. 15

17 AUBAGIO Aubagio PA Other All FDA-approved indications not otherwise excluded from Part D Concurrent use of Aubagio with other disease-modifying agents used for multiple sclerosis (MS) MS, patient must have a relapsing form of MS (RRMS, SPMS with relapses, or PRMS). MS, previous MS therapies tried. Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS. 16

18 AVONEX Avonex (with albumin) Avonex intramuscular pen injector kit Avonex intramuscular syringe kit PA Other All FDA approved indications not otherwise excluded from Part D Concurrent use of other disease-modifying agents used for multiple sclerosis (MS) Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS. Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS. 17

19 BANZEL Banzel oral tablet PA Other All FDA-approved indications not otherwise excluded from Part D 18

20 BAVENCIO Bavencio PA Other All FDA-approved indications not otherwise excluded from Part D For urothelial carcinoma, treatment naive patients For urothelial carcinoma, previous treatment with platinum-containing chemotherapy Prescribed by, or in consultation with, an oncologist For Locally Advanced or Metastatic Urothelial Carcinoma patient must have disease progression during or after platinum-containing chemotherapy or within of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy 19

21 BENLYSTA Benlysta subcutaneous PA Other All FDA-approved indications not otherwise excluded from Part D Patients with severe lupus nephritis or severe active central nervous system lupus, concurrent use with other biologics or intravenous cyclophosphamide Diagnosis, patient has active, autoantibody-positive, systemic lupus erythematosus and is receiving standard therapy 18 years of age or older Prescribed by, or in consultation with, a rheumatologist, or a physician that specializes in diseases of joints and muscles 20

22 BOSULIF Bosulif PA Other All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Bosulif for a Covered Use. Diagnosis for which Bosulif is being used. For chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) status of the leukemia must be reported. For CML, prior therapies tried must be reported to confirm resistance or intolerance. Prescribed by, or in consultation with, an Oncologist For CML, patient must have Ph-positive CML and must have resistance or intolerance to any one prior therapy for approval. 21

23 BRIVIACT Briviact PA Other All FDA-approved indications not otherwise excluded from Part D 22

24 CABOMETYX Cabometyx PA All medically accepted indications not otherwise excluded from Part D Diagnosis, medication history, histology, RET gene rearrangement status Prescribed by, or in consultation with, an Oncologist Other Advance Renal Cell Carcinoma-Patients must meet both 1 AND 2-1. Patient has RCC with predominant clear-cell histology 2. Patient has tried one tyrosine kinase inhibitor therapy (e.g., Sutent [sunitinib malate capsules], Votrient [pazopanib tablets], Inlyta [axitinib tablets], Nexavar [sorafenib tosylate tablets]). 23

25 CALQUENCE Calquence PA Other All FDA-approved indications not otherwise excluded from Part D Previous treatment with a BTK inhibitor (e.g. Imbruvica) Diagnosis, previous therapies tried 18 years of age or older Prescribed by, or in consultation with, an oncologist For mantle cell lymphoma (MCL), patient has received at least one prior therapy 24

26 CHOLBAM Cholbam PA All FDA approved indications not otherwise excluded from Part D baseline liver function tests Prescribed by or in consultation with hepatologist, metabolic specialist, or GI Initial approval for 3 months, continuation approval for plan year Other For continuation of therapy to be approved patient must meet 2 of the 3 following lab criteria or meet 1 of the 3 follow lab criteria and have body weight increased by 10% or stable at greater than the 50th percentile. Lab criteria: (1) patient alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 50 U/L or the baseline levels reduced by 80%, (2) patient total bilirubin level must be reduced to less than or equal to 1 mg/dl, (3) patient must not have evidence of cholestasis on liver biopsy. 25

27 CHORIONIC GONADOTROPINS (HCG) chorionic gonadotropin, human Novarel intramuscular recon soln 10,000 unit Pregnyl PA All medically accepted indications not otherwise excluded from Part D. Other 26

28 CIALIS Cialis oral tablet 2.5 mg, 5 mg PA All FDA-approved indications not otherwise excluded from Part D. Other Indication for which tadalafil is being prescribed. Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED) and after a trial of an alpha-1 blocker (eg, doxazosin [Cardura XL], terazosin, tamsulosin [Flomax], alfuzosin extended-release [UroXatral]) or 5 alpha reductase inhibitor (eg, finasteride, dutasteride [Avodart]). 27

29 CINRYZE Cinryze PA All FDA-approved indications not otherwise excluded from Part D. Other Must be prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders. 28

30 COMETRIQ Cometriq PA Other All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Cometriq for a Covered Use. Diagnosis of progressive, metastatic medullary thyroid cancer. Prescribed by, or in consultation with, an Oncologist 29

31 CORLANOR Corlanor PA All FDA-approved indications not otherwise excluded from Part D. Previous use of a Beta-blocker, LVEF, sinus rhythm, and resting HR Other HF in pts not currently receiving Corlanor - must all of the following 1. have LVEF of less than or equal 35 percent, 2. have sinus rhythm and a resting HR of greater than or equal to 70 BPM, AND 3. tried or is currently receiving a Beta-blocker for HF (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol, carvedilol ER) unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). HF in pts currently receiving Corlanor - had a LVEF of less than or equal to 35 percent prior to initiation of Corlanor therapy AND has tried or is currently receiving a Beta-blocker for HF unless the patient has a contraindication to the use of beta blocker therapy. 30

32 COTELLIC Cotellic PA Other All FDA-approved indications not otherwise excluded from Part D Previous therapies tried, presence of BRAF V600E or V600K mutation confirmed by an FDA approved test 18 years and older Prescribed by, or in consultation with, an Oncologist Melanoma - being prescribed in combination with vemurafenib 31

33 CRINONE Crinone PA Other All FDA-approved indications not otherwise excluded from Part D Use in patients to supplement or replace progesterone in the management of infertility. Secondary amenorrhea,. Support of an established pregnancy, 9 months. 32

34 CYRAMZA Cyramza PA Other All FDA-approved indications not otherwise excluded from Part D Previous therapies tried Prescribed by, or in consultation with, an Oncologist For gastric cancer or malignant neoplasm of cardio-esophageal junction of stomach, prior therapy with fluoropyrimidine- or platinum-containing therapy. For metastatic colorectal cancer, in combination with 5- fluorouracil, leucovorin, irinotecan (FOLFIRI) and prior therapy with Avastin (bevacizumab), oxaliplatin, and a fluoropyrimidine. For metastatic NSCLC, in combination with docetaxel and prior therapy with platinumbased chemotherapy. Part B versus D determination per CMS guidance. 33

35 DARAPRIM Daraprim PA Other All FDA-approved indications not otherwise excluded from Part D coverage hypersensitivity to pyrimethamine, documented megaloblastic anemia due to folate deficiency Medication history, patient's immune status Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist. Malaria Prophylaxis, approve if the patient has tried at least two other antimalarials (eg, atovaquone-proguanil, chloroquine phosphate, hydroxychloroquine sulfate, doxycycline, mefloquine, and primaquine). Malaria Treatment, approve if the patient has tried at least two other antimalarials (eg, Coartem [artemether-lumefantrine tablets], quinine sulfate or quinidine gluconate in combination with doxycycline, tetracycline, or clindamycin, quinine sulfate in combination with primaquine and either doxycycline or tetracycline, or the following medications as monotherapy or in combination with primaquine: atovaquone-proguanil, mefloquine, chloroquine phosphate, and hydroxychloroquine). Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed and the patient has tried one other recommended 34

36 PA therapy, unless contraindicated (eg, trimethoprim-sulfamethoxazole [TMP- SMX], atovaquone). 35

37 DARZALEX Darzalex PA Other All FDA-approved indications not otherwise excluded from Part D Treatment-naive patients History of previous treatments Prescribed by, or in consultation with, an Oncologist For the treatment of Multiple myeloma as monotherapy, patients must have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or are double-refractory to a PI and an immunomodulatory agent. For the treatment of Multiple myeloma in combination with pomalidomide and dexamethasone, patients must have received at least two prior therapies including lenalidomide and a proteasome inhibitor. For the treatment of Multiple myeloma, In combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone patients must have received at least one prior therapy. 36

38 DEMSER Demser PA All FDA-approved indications not otherwise excluded from Part D. Other 37

39 DICLOFENAC GEL diclofenac sodium topical gel 3 % PA Other All FDA approved indications not otherwise excluded from Part D 38

40 DIGOXIN Digitek digoxin injection solution digoxin oral solution 50 mcg/ml digoxin oral tablet PA Other All FDA-approved indications not otherwise excluded from Part D coverage The physician has documented the indication for the continued use of the HRM (high risk medication) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not appropriate for the patient. This prior authorization only applies to members 65 years of age or older to ensure safe use of a potentially high risk medication in the elderly population. Members under 65 years of age are not subject to the prior authorization requirements. 39

41 DUPIXENT Dupixent PA Other All FDA-approved indications not otherwise excluded from Part D Treatment naive patients Diagnosis, previous therapies tried and lengths of trials, percentage of body surface area affected 18 years of age or older Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist. Initiation 16 weeks, Continuation Initial therapy patient has atopic dermatitis involvement estimated to be over 10% of the body surface area (BSA), AND patient has used at least one medium, medium-high, high, and/or super-high-potency prescription topical corticosteroid for at least 30 consecutive days AND the patient has tried tacrolimus ointment for at least 30 consecutive days AND inadequate efficacy was demonstrated with topical therapy, according to the prescribing physician. Continuation Approve if the patient has responded to Dupixent therapy as determined by the prescribing physician (e.g., marked improvements in erythema, induration,papulation,edema, excoriations, and lichenification, reduced pruritus, decreased requirement for other topical or systemic therapies, reduced body surface area (BSA) affected with atopic dermatitis, or other responses observed). 40

42 EGRIFTA Egrifta subcutaneous recon soln 1 mg PA All FDA approved indications not otherwise excluded from Part D. Other Diagnosis. Adults Prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of HIV (eg, infectious disease, oncology). HIV-infected adult patients (18 years of age or older) with lipodystrophy AND Egrifta is being used to reduce excessive abdominal fat 41

43 EMPLICITI Empliciti PA Other All FDA-approved indications not otherwise excluded from Part D Treatment-naive patients History of previous treatments Prescribed by, or in consultation with, an Oncologist For the treatment of multiple myeloma, patient must have received at least one prior therapy. Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. 42

44 EPCLUSA Epclusa PA Other All FDA-approved indications not otherwise excluded from Part D Combination use with other direct acting antivirals, excluding ribavirin. Documentation from the medical record of diagnosis including genotype, HCV RNA viral levels prior to treatment, history of previous HCV therapies, and presence/absence of cirrhosis. For patients with cirrhosis, cirrhosis must be documented by FibroScan, FibroTest ActiTest, liver biopsy, or radiological imaging. 18 years or older Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician. 12 weeks, based on indication and current AASLD/IDSA guidance. will be applied consistent with current AASLD/IDSA guidance 43

45 ERIVEDGE Erivedge PA Other All FDA-approved indications not otherwise excluded from Part D. Plus, patient already started on Erivedge for a covered use. Prescribed by, or in consultation with, an Oncologist Locally advanced basal cell carcinoma (LABCC), approve if the patients BCC has recurred following surgery or the patient is not a candidate for surgery or radiation therapy. 44

46 ERLEADA Erleada PA All FDA-approved indications not otherwise excluded from Part D. Other Pregnancy Documentation from medical records of diagnosis. For non-metastatic castration-resistant prostate cancer, prior therapies tried. 18 years of age and older Prescribed by, or in consultation with, an Oncologist For prostate cancer, patient must have non-metastatic, castration-resistant prostate cancer for approval. Patient must be receiving Erleada in combination with a gonadotropin-releasing hormone (GnRH) analog OR had a bilateral orchiectomy. 45

47 ERWINAZE Erwinaze PA Other All FDA-approved indications not otherwise excluded from Part D Documentation of hypersensitivity to Escherichia coli derived asparaginase as a component of a multi-agent chemotherapeutic regimen. Prescribed by, or in consultation with, an Oncologist or Hematologist 46

48 ESBRIET Esbriet PA All FDA-approved indications not otherwise excluded from Part D. Other Combination use with Nintedanib 18 years of age and older Prescribed by or in combination with a pulmonologist IPF baseline - must have FVC greater than or equal to 50 percent of the predicted value AND IPF must be diagnosed with either findings on highresolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. 47

49 EXTAVIA Extavia subcutaneous kit PA Other All FDA approved indications not otherwise excluded from Part D Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate. Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS. Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS. Patients with previous use (12 or more months) of Extavia must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, MRI lesions have diminished with therapy, OR patient is stable on therapy. 48

50 FABRAZYME Fabrazyme PA Other All FDA-approved indications not otherwise excluded from Part D 49

51 FARYDAK Farydak PA Other All FDA-approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, an Oncologist or Hematologist Must be used in combination with Velcade and dexamethasone AND previously tried Velcade and one immunomodulatory drug (i.e., Thalomid, Revlimid, or Pomalyst). 50

52 FERRIPROX Ferriprox oral tablet PA Other All FDA approved indications not otherwise excluded from Part D 51

53 FIRAZYR Firazyr PA Other All FDA approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders. 52

54 FYCOMPA Fycompa oral suspension Fycompa oral tablet PA Other All FDA-approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, a Neurologist 53

55 GATTEX Gattex 30-Vial PA Other All FDA approved indications not otherwise excluded from Part D 54

56 GILOTRIF Gilotrif PA Other All FDA-approved indications not otherwise excluded from Part D For metastatic non-small cell lung cancer (NSCLC) documentation of nonresistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. For metastatic squamous NSCLC, documentation of prior platinum-based chemotherapy. Prescribed by, or in consultation with, an Oncologist 55

57 GLATOPA/COPAXONE glatiramer Glatopa PA All FDA-approved indications not otherwise excluded from Part D. Other Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate. Previous therapies tried. Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS. Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS. Patients with previous use (12 or more months) of Glatopa/glatiramer must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, diminished MRI lesions, OR patient is stable on therapy. 56

58 GROWTH HORMONE Norditropin FlexPro PA Other All medically accepted indications not otherwise excluded from Part D For pediatric GHD in neonate with hypoglycemia: patient has a randomly assessed GH level less than 20 ng/ml, other causes of hypoglycemia have been ruled out, and other treatments have been ineffective. For all pediatric patients: patients have short stature or slow growth velocity and have been evaluated for other causes of growth failure. For pediatric GHD, patient has delayed bone age. For pediatric GHD without pituitary disease, patient failed 2 stimulation tests. For pediatric GHD with a pituitary or CNS disorder, patient has clinical evidence of GHD and low IGF-1/IGFBP3. For TS and SHOX patients: diagnosis confirmed by genetic testing. For CRI patients: metabolic, endocrine and nutritional abnormalities have been treated or stabilized and patient has not had a kidney transplant. For SGA: patient has a low birth weight or length for gestational age. For ISS: pediatric GHD has been ruled out with one stimulation test. For adult GHD, patient was assessed for other causes of GHD-like symptoms. For adult GHD without pituitary disease, patient failed 2 stimulation tests. For adult GHD with at least 3 pituitary hormone deficiencies (PHD) or panhypopituitarism: have a low IGF-1. For adult GHD with less than 3 PHD, low IGF-1 and failed one stimulation test. For renewal: patient has seen clinical improvement. For Turner syndrome and SGA, 2 years of age and older. For Noonan syndrome and SHOX, 3 years of age and older. Endocrinologist, Pediatric Nephrologist, Gastroenterologist, Nutritional Support Specialist, Infectious Disease Specialist 57

59 HARVONI Harvoni PA All FDA-approved indications not otherwise excluded from Part D. Other Combination use with other direct acting antivirals, excluding ribavirin. Documentation from the medical record of diagnosis including genotype, HCV RNA viral levels prior to treatment, history of previous HCV therapies, and presence/absence of cirrhosis. For patients with cirrhosis, cirrhosis must be documented by FibroScan, FibroTest ActiTest, liver biopsy, or radiological imaging. 12 years of age and older Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician. 12 to 24 weeks, based on indication and current AASLD/IDSA guidance. will be applied consistent with current AASLD/IDSA guidance 58

60 HETLIOZ Hetlioz PA Other All FDA approved indications not otherwise excluded from Part D For the indication of Non-24-Hour Sleep-Wake Disorder (Non-24), approval will only be granted for patients who are totally blind. 59

61 HRM benztropine oral butalbital-acetaminop-caf-cod butalbital-acetaminophen-caff oral capsule clemastine oral tablet 2.68 mg cyclobenzaprine oral tablet cyproheptadine ergoloid meprobamate metaxalone methyldopa-hydrochlorothiazide promethazine oral tablet trihexyphenidyl PA Other All FDA approved indications not otherwise excluded from Part D Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy 60

62 HRM - BENZODIAZEPINES alprazolam oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg lorazepam oral oxazepam temazepam PA All medically accepted indications not otherwise excluded from Part D. Other Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. Procedure-related sedation = 1mo. All other conditions = Plan Year. All medically accepted indications other than insomnia, authorize use. Insomnia, approve lorazepam, oxazepam, or temazepam if the patient has had a trial with two of the following: ramelteon, trazodone, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon. 61

63 HRM BENZODIAZEPINES/ANTICONVULSANTS clonazepam oral tablet,disintegrating clorazepate dipotassium Diazepam Intensol diazepam oral solution 5 mg/5 ml (1 mg/ml) diazepam oral tablet PA Other All FDA approved indications not otherwise excluded from Part D Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy 62

64 HRM PD amitriptyline clomipramine doxepin oral estradiol oral imipramine HCl imipramine pamoate megestrol oral tablet perphenazine-amitriptyline phenobarbital trimipramine PA All FDA-approved indications not otherwise excluded from Part D. Other Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy 63

65 HYDROXYPROGESTERONE hydroxyprogesterone caproate PA Other All FDA-approved indications not otherwise excluded from Part D 64

66 IBRANCE Ibrance PA Other All FDA-approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, an Oncologist 65

67 ICLUSIG Iclusig PA Other All FDA-approved indications not otherwise excluded from Part D Diagnosis the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status CML/ALL - Adults Prescribed by, or in consultation with, an Oncologist CML Ph+, T315I-positive or has tried TWO other TKIs indicated for use in Philadelphia chromosome positive CML (e.g., Gleevec, Sprycel, Tasigna). ALL Ph+, T315I-posistive or has tried TWO other TKIs indicated for use in Ph+ ALL (e.g. Gleevec, Sprycel.) 66

68 IDHIFA Idhifa PA Other All FDA-approved indications not otherwise excluded from Part D Acute myeloid leukemia without the presence of the isocitrate dehydrogenase-2 (IDH2) mutation Diagnosis, documentation of the presence of the isocitrate dehydrogenase-2 (IDH2) mutation in the blood or bone marrow as detected by an FDAapproved test 18 years of age or older Prescribed by, or in consultation with, an oncologist For relapsed or refractory acute myeloid leukemia, patient has the isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test 67

69 ILARIS Ilaris (PF) subcutaneous solution PA All FDA-approved indications not otherwise excluded from Part D. Other When used in combination with concurrent biologic therapy (e.g.tnf antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or rilonacept. CAPS-4 years of age and older. SJIA-2 years of age and older. CAPS/MWS/FCAS initial- Prescribed by or in consultation with a rheumatologist, geneticist, immunologist or dermatologist. SJIA initialprescribed by or in consultation with a rheumatologist For renewal of CAPS/MWS/FCAS - after pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician and the pt is continuing therapy to maintain a response/remission. For treatment of SJIA, initial therapy approve if the pt meets one of the following 1. has tried at least 2 other biologics for SJIA (tocilizumab, abatacet, TNF antagonists (e.g. etanercept, adalimumab, infliximab) OR 2. pt has features of poor prognosis (e.g. arthritis of the hip, radiographic damage, 6-month duration of significant active systemic disease, defined by fever, elevated inflammatory markers, or requirement for treatment with systemic glucocorticoids AND tried Actemra or Kineret. SJIA renewal approve if it patient was already started on Ilaris and the pt had a response (e.g. resolution of fever, improvement in limitations of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or ADLs, reduced dosage of CS) and the pt is continuing therapy to maintain response/remission. 68

70 IMATINIB/GLEEVEC imatinib oral tablet 100 mg, 400 mg PA Other All FDA approved indications not otherwise excluded from Part D Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed, 2) resistance or intolerance to prior therapy, or 3) recurrence after stem cell transplant. For ALL, patient meets one of the following: 1) newly diagnosed and imatinib is used in combination with chemotherapy, or 2) ALL is relapsed or refractory. For GIST, patient meets one of the following: 1) unresectable, recurrent, or metastatic disease, or 2) use of imatinib for adjuvant therapy following resection, or 3) use of imatinib for pre-operative therapy and patient is at risk for significant surgical morbidity. Prescribed by, or in consultation with, an Oncologist 69

71 IMBRUVICA Imbruvica oral capsule 140 mg, 70 mg Imbruvica oral tablet PA Other All FDA-approved indications not otherwise excluded from Part D For patients with mantle cell lymphoma (MCL)-history of prior treatment. Prescribed by, or in consultation with, an Oncologist 70

72 IMFINZI Imfinzi PA Other All FDA-approved indications not otherwise excluded from Part D Treatment naive patients, pregnancy Diagnosis, prior treatment with platinum-based chemotherapy 18 years or older Prescribed by or in consultation with an oncologist For locally advanced or metastatic urothelial carcinoma, patient had disease progression during or following platinum-containing chemotherapy or patient had disease progression within of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 71

73 INGREZZA Ingrezza PA Other All FDA-approved indications not otherwise excluded from Part D Diagnosis, previous therapies tried 18 years or older Prescribed by, or in consultation with, a neurologist or psychiatrist Patient has a diagnosis of moderate to severe tardive dyskinesia AND a history of current or previous chronic use of an antipsychotic or other dopamine antagonist. 72

74 INLYTA Inlyta PA Other All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Inlyta for a Covered Use. Prescribed by, or in consultation with, an Oncologist Advanced renal cell carcinoma, approve the patient has failed at least one prior systemic therapy (eg, Torisel, Avastin, Sutent, IFN-alpha, IL-2, Votrient, Nexavar). 73

75 IRESSA Iressa PA Other All FDA-approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, an Oncologist Metastatic NSCLC - The patient has epidermal growth factor receptor (EGFR) exon 19 deletions OR has exon 21 (L858R) substitution mutations as detected by an FDA-approved test. 74

76 IVIG Gammagard Liquid Gamunex-C injection solution 1 gram/10 ml (10 %) PA All medically accepted indications not otherwise excluded from Part D. Other Authorization will be for Plan Year. Part B versus D determination per CMS guidance to establish if drug used for PID in pts home. 75

77 JAKAFI Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg PA Other All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Jakafi for a Covered Use. Prescribed by, or in consultation with, an Oncologist or Hematologist For polycythemia vera patients must have tried hydroxyurea 76

78 JUXTAPID Juxtapid PA Other All FDA approved indications not otherwise excluded from Part D 77

79 KADCYLA Kadcyla PA All FDA-approved indications not otherwise excluded from Part D. Other HER2 overexpression status. Prior therapies tried. Prescribed by, or in consultation with, an Oncologist 78

80 KALYDECO Kalydeco PA Other All FDA approved indications not otherwise excluded from Part D Patients with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene. CF mutation test documenting a G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene. 2 years of age and older for packets. 6 years of age and older for tablets. Prescribed by or inconsultation with a pulmonologist or a physician who specializes in CF 79

81 KEVEYIS Keveyis PA Other All FDA-approved indications not otherwise excluded from Part D Patient with history of hypersensitivity to diclorphenamide or other sulfonamides, Patient on high dose aspirin, Patient with severe pulmonary disease, Patient with hepatic insufficiency Initial therapy - 2 months, Continuing therapy - plan year Hyperkalemic Periodic Paralysis (HyperPP) and Related Variants: Patient has a confirmed diagnosis of primary hyperkalemic periodic paralysis by meeting at least ONE of the following criteria: Patient has had an increase from baseline in serum potassium concentration of greater than or equal to 1.5 meq/l during a paralytic attack OR Patient has had a serum potassium concentration during a paralytic attack of greater than 5.0 meq/l OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle sodium channel mutation AND The prescribing physician has excluded other reasons for acquired hyperkalemia (e.g., drug abuse, renal and adrenal dysfunction) For Continuation of treatment a patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician. For Hypokalemic Periodic Paralysis (HypoPP) and Related Variants for Initiation of treatment: Patient has a confirmed diagnosis of primary hypokalemic periodic paralysis by meeting at least ONE of the following: Patient has had a serum potassium concentration of less than 3.5 meq/l during a paralytic attack OR Patient has a family history of the condition OR Patient 80

82 PA has a genetically confirmed skeletal muscle calcium or sodium channel mutation AND Patient has had improvements in paralysis attack symptoms with potassium intake. For Continuation of treatment: Patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician 81

83 KEYTRUDA Keytruda intravenous solution PA All FDA-approved indications not otherwise excluded from Part D. Other For NSCLC, PD-L1 status and prior therapies tried. Prescribed by, or in consultation with, an Oncologist 82

84 KISQALI Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 1)-2.5 mg, 400 mg/day(200 mg x 2)-2.5 mg, 600 mg/day(200 mg x 3)-2.5 mg Kisqali oral tablet 200 mg/day (200 mg x 1), 400 mg/day (200 mg x 2), 600 mg/day (200 mg x 3) PA Other All FDA-approved indications not otherwise excluded from Part D Use as monotherapy, pregnancy Estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopause status, previous therapies tried 18 years or older Prescribed by, or in consultation with, an oncologist For advanced (metastatic) breast cancer, patient has estrogen receptorpositive, human epidermal growth factor receptor 2-negative (ER-positive, HER2-negative) breast cancer and patient is postmenopausal and, for patients who have not previously received endocrine therapy for advanced disease, Kisqali must be used in combination with an aromatase inhibitor (anastrozole, exemestane, letrozole) 83

85 KORLYM Korlym PA Other All FDA approved indications not otherwise excluded from Part D Pregnancy. Patients taking simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses. Women with a history of unexplained vaginal bleeding. Women with endometrial hyperplasia with atypia or endometrial carcinoma. 84

86 KUVAN Kuvan oral tablet,soluble PA Other All FDA approved indications not otherwise excluded from Part D Blood phenylalanine (Phe) levels. Pretreatment blood phenylalanine (Phe) levels greater than 10mg/dL if the patient is older than 12 years of age or greater than 6mg/dL if less than or equal to 12 years of age. Response to a therapeutic trial (greater than or equal to a 30% reduction in blood Phe levels) is required for long-term authorization. 2 months initial, plan year on renewal Blood Phe levels should be checked after 1 week of therapy and periodically up to one month during a therapeutic trial. 85

87 KYNAMRO Kynamro PA Other All FDA-approved indications not otherwise excluded from Part D Current LDL-C (within the past 30 days), prior therapies tried For HoFH approve after trial of Repatha. 86

88 KYPROLIS Kyprolis PA Other All FDA-approved indications not otherwise excluded from Part D Diagnosis, prior therapies 18 years or older Prescribed by or in consultation with Oncologist or hematologist For Relapsed or Refractory Multiple Myeloma, patient has tried at least one prior therapy. 87

89 LARTRUVO Lartruvo PA Other All FDA-approved indications not otherwise excluded from Part D Diagnosis, prior therapies 18 years or older Prescribed by or in consultation with Oncologist For the treatment of adult patients with soft tissue sarcoma (STS) must be used in combination with doxorubicin. 88

90 LENVIMA Lenvima PA Other All FDA-approved indications not otherwise excluded from Part D Prescribed by, or in consultation with, an Oncologist DTC - must be locally recurrent or metastatic, progressive refractory to radioactive iodine treatment for approval 89

91 LETAIRIS Letairis PA Other All FDA approved indications not otherwise excluded from Part D Pregnancy, idiopathic pulmonary fibrosis, including idiopathic pulmonary fibrosis patients with pulmonary hypertension (WHO group 3). Prescribed by or in consultation with a cardiologist or pulmonologist UD or two appropriate contraceptive methods will be used for women of childbearing potential. 90

92 LEUKINE Leukine injection recon soln PA Other All FDA approved indications not otherwise excluded from Part D Administration within 24 hours preceding or following chemotherapy or radiotherapy, hypersensitivity to yeast-derived products. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule above established regimens. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle. For AML only, excessive (greater than or equal to 10%) leukemic myeloid blasts in the bone marrow or peripheral blood. For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Leukine may be used for the prevention of chemotherapyinduced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Leukine is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Leukine (or Neupogen) OR in patients at risk for infection-related complications. 6 months 91

93 LEUPROLIDE Eligard Eligard (3 month) Eligard (4 month) Eligard (6 month) leuprolide subcutaneous kit Lupron Depot Lupron Depot (3 month) Lupron Depot (4 month) Lupron Depot (6 Month) Lupron Depot-Ped (3 month) intramuscular syringe kit 30 mg Lupron Depot-Ped intramuscular kit mg, 15 mg PA Other All FDA-approved indications not otherwise excluded from Part D but specific to the following drugs as follows: Prostate cancer (Lupron Depot [7.5 mg-1mo, 22.5 mg-3-mo, 30 mg-4-mo, 45 mg-6-mo] OR Eligard [7.5 mg-1-mo, 22.5mg-3-mo, 30 mg-4-mo, 45 mg-6-mo]), Endometriosis (Lupron Depot [3.75 mg-1-mo, mg-3-mo]), Uterine leiomyomata (Lupron Depot [3.75 mg-1-mo, mg-3-mo]), Treatment of central precocious puberty (Lupron Depot Ped [11.25 mg-1-mo, 15 mg-1-mo]). Ovarian cancer (Lupron Depot [7.5 mg-1-mo]). Breast cancer (Lupron Depot [3.75 mg-1-mo, mg-3-mo]). Prophylaxis or treatment of uterine bleeding in premenopausal women with hematologic malignancy or prior to bone marrow/stem cell transplantation (BMT/SCT) (Lupron Depot [3.75 mg-1-mo, 7.5 mg-1-mo]). For abnrml uterine bleeding, uterine leiomyomata,endometriosis-6 mo.all other=plan Year 92

94 LIDOCAINE PATCH lidocaine topical adhesive patch,medicated PA Other All FDA-approved indications not otherwise excluded from Part D. Plus diabetic neuropathic pain. For diabetic neuropathic pain: the patient must have previous use and inadequate response or intolerance to any ONE medication that is FDAlabeled for diabetic peripheral neuropathy, including (but not limited to) duloxetine and Lyrica. 93

95 LINEZOLID linezolid linezolid in dextrose 5% PA Other All FDA-approved indications not otherwise excluded from Part D Culture and sensitivity and CBC within normal limits 28 days 94

96 LONSURF Lonsurf PA Other All FDA-approved indications not otherwise excluded from Part D Treatment-naive patients Prescribed by, or in consultation with, an Oncologist For Metastatic colorectal cancer, patient must have previously been treated with a fluoropyrimidine (e.g., capecitabine, 5-FU) AND oxaliplatin AND irinotecan AND an anti-vegf therapy And if RAS wild type, ananti- EGFR therapy. 95

97 LYNPARZA Lynparza PA Other All FDA-approved indications not otherwise excluded from Part D A deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer as detected by an FDA-approved test. Prescribed by, or in consultation with, an Oncologist A documented diagnosis of advanced ovarian cancer which has been treated with at least three prior lines of chemotherapy. 96

98 MAVYRET Mavyret PA Other All FDA-approved indications not otherwise excluded from Part D Combination use with other direct acting antivirals, excluding ribavirin. Documentation from the medical record of diagnosis including genotype, HCV RNA viral levels prior to treatment, history of previous HCV therapies, and presence/absence of cirrhosis. For patients with cirrhosis, cirrhosis must be documented by FibroScan, FibroTest ActiTest, liver biopsy, or radiological imaging. 18 years of age and older Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician. 8 to 16 weeks, based on indication and current AASLD/IDSA guidance. will be applied consistent with current AASLD/IDSA guidance 97

99 MEGESTROL megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml PA Other All FDA-approved indications not otherwise excluded from Part D 98

100 MEKINIST Mekinist PA Other All FDA-approved indications not otherwise excluded from Part D Documentation of the detected BRAFV600E or BRAFV600K mutation 99

101 METHAMPHETAMINE methamphetamine PA All FDA-approved indications not otherwise excluded from Part D. Other 100

102 MYLOTARG Mylotarg PA Other All FDA-approved indications not otherwise excluded from Part D Patients with CD33-negative acute myeloid leukemia (AML), newlydiagnosed pediatric patients Diagnosis, patient has CD33-positive AML, current treatment regimen if Mylotarg is being used as combination therapy, for pediatric patients, treatment history 2 years of age or older Prescribed by, or in combination with, an oncologist or a hematologist For pediatric patients with CD-33 positive AML, patient must have been previously treated and has relapsed or refractory disease. For newly diagnosed adult patients with CD-33 positive AML, if Mylotarg is being used as part of a combination regimen, patient is also receiving daunorubicin and cytarabine induction and consolidation therapy 101

103 NAMENDA memantine oral capsule,sprinkle,er 24hr memantine oral solution memantine oral tablet memantine oral tablets,dose pack Namenda XR PA Other All FDA approved indications not otherwise excluded from Part D 102

104 NATPARA Natpara PA Other All FDA approved indications not otherwise excluded from Part D Hypoparathyroidism caused by calcium-sensing receptor mutations. Patients with acute post-surgical hypoparathyroidism. Serum calcium level 18 years of age and older For diagnosis of hypocalcemia in patients with hypoparathyroidism, documentation required to show hypocalcemia is not corrected by calcium supplements and active forms of vitamin D alone. 103

105 NERLYNX Nerlynx PA Other All FDA-approved indications not otherwise excluded from Part D Trastuzumab treatment naive patients, HER2-negative patients, ALT greater than 5-20 times the upper limit of normal, bilirubin greater than 3-10 times the upper limit of normal, concomitant use with gastric acid reducing agents (PPIs, H2-receptor antagonists, antacids Diagnosis, human epidermal growth factor receptor 2 (HER2) status, previous therapies tried, patient has early stage breast cancer 18 years of age or older Prescribed by, or in consultation with, an oncologist Nerlynx is being used for extended adjuvant treatment of early stage breast cancer with HER2 overexpression and patient has received adjuvant treatment with trastuzumab based therapy 104